3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Ovarian Neoplasms
3
Hodgkin Disease
2
Fallopian Tube Neoplasms
2
Endometrial Neoplasms
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Peritoneal Neoplasms
1
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
Lymphoma, T-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Glioma
1
Estrogen Receptor and/or Progesterone Receptor Positive
1
Endometrial Hyperplasia
1
Diffuse Intrinsic Pontine Glioma
1
Carcinoma, Non-Small-Cell Lung
1
Calcinosis
1
Breast Neoplasms
1
Brain Neoplasms
1
Adrenal Cortex Neoplasms
1
Interventions
Radiotherapy
5
Temozolomide
4
Radiation
3
Irinotecan
3
Bevacizumab
3
ribociclib
2
abemaciclib
2
Vorinostat
2
Mebendazole
2
Everolimus
2
Dasatinib
2
vandetanib
1
temsirolimus
1
sargramostim
1
reolysin
1
pembrolizumab
1
ovex
1
nimotuzumab
1
irinotecan sucrosofate
1
dinutuximab
1
crenolanib
1
adavosertib
1
Vincristine
1
Valproic Acid
1
Sirolimus
1
Re-Irradiation
1
Radiotherapy, Intensity-Modulated
1
Radiotherapy, Conformal
1
Radiation Dose Hypofractionation
1
Piperazine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Diffuse Intrinsic Pontine Glioma
×
Pharmacogenomic Variants
×
Clear all
NCT01165333
2026-03-16
CILENT
Centre Oscar Lambret
Phase 1
Completed
32 enrolled